Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive

Molecular Therapy

Volumn 13, Issue 2, 2006, Pages 289-300

  Kim, Seon Hee ^a   Bianco, Nicole ^a   Menon, Rajasree ^a   Lechman, Eric R ^a   Shufesky, William J ^a,b   Morelli, Adrian E ^a,b   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; Dendritic cells; Exosomes; Fas ligand; Suppression

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE SEVERITY; DNA MODIFICATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELIVERY SYSTEM; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD95; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EXOSOMES; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA;

ANIMALIA; MURINAE;

EID: 30344460536     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.09.015     Document Type: Article

References (44)

1. C.H. Evans and P.D. Robbins Prospects for treating arthritis by gene therapy J. Rheumatol. 21 1994 779-782
2. P.D. Robbins and C.H. Evans Prospects for treating autoimmune and inflammatory diseases by gene therapy Gene Ther. 3 1996 187-189
3. C.H. Evans and P.D. Robbins Pathways to gene therapy in rheumatoid arthritis Curr. Opin. Rheumatol. 8 1996 230-234
4. C.H. Evans et al. Gene therapy for rheumatic diseases Arthritis Rheum. 42 1999 1-16
5. S.C. Ghivizzani T.J. Oligino J.C. Glorioso P.D. Robbins and C.H. Evans Gene therapy approaches for treating rheumatoid arthritis Clin. Orthop. 379 2000 S288-S299
6. W.P. Arend IL-1 antagonism in inflammatory arthritis Lancet 341 1993 155-156
7. G. Bandara et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer Proc. Natl. Acad. Sci. USA 90 1993 10764-10768
8. S.C. Ghivizzani et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects Proc. Natl. Acad. Sci. USA 95 1998 4613-4618
9. L. Mori S. Iselin G. De Libero and W. Lesslauer Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice J. Immunol. 157 1996 3178-3182
10. L.A. Joosten M.M. Helsen F.A. van de Loo and W.B. van den Berg Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNF alpha, anti-IL-1 alpha/ beta, and IL-1Ra Arthritis Rheum. 39 1996 797-809
11. S.-H. Kim C.H. Evans S. Kim T.J. Oligino S.C. Ghivizzani and P.D. Robbins Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4 Arthritis Res. 2 2000 293-302
12. K.N. Kim S. Watanabe Y. Ma S. Thornton E.H. Giannini andv R. Hirsch Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer J. Immunol. 164 2000 1576-1581
13. E.R. Lechman et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees J. Immunol. 163 1999 2202-2208
14. S.C. Ghivizzani et al. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: Implications for arthritis gene therapy Gene Ther. 4 1997 977-982
15. A. Ceponis et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits Arthritis Rheum. 44 2001 1908-1916
16. S.H. Kim E.R. Lechman S. Kim J. Nash T.J. Oligino and P.D. Robbin Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis Mol. Ther. 6 2002 591-600
17. J.D. Whalen A.W. Thomson L. Lu P.D. Robbins and C.H. Evans Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: Evidence for involvement of genetically modified dendritic cells and macrophages Mol. Ther. 4 2001 543-550
18. S.-H. Kim S. Kim C.H. Evans S.C. Ghivizzani T. Oligino and P.D. Robbins Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 J. Immunol. 166 2001 3499-3505
19. S.-H. Kim S. Kim T.J. Oligino and P.D. Robbins Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL Mol. Ther. 6 2002 584-590
20. Y. Morita et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis J. Clin. Invest. 107 2001 1275-1284
21. H.G. Zhang et al. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice J. Immunol. 168 2002 4164-4172
22. H.G. Zhang et al. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice J. Clin. Invest. 105 2000 813-821
23. H.G. Zhang et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells Nat. Biotechnol. 16 1998 1045-1049
24. W.P. Min et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival J. Immunol. 164 2000 161-167
25. J.G. Culvenor T.E. Mandel A. Whitelaw and E. Ferber Characteristics of plasma membrane isolated from a mouse T lymphoma line: Comparison after nitrogen cavitation, shearing, detergent treatment, and microvesiculation J. Cell. Biochem. 20 1982 127-138
26. R.M. Johnstone M. Adam J.R. Hammond L. Orr and C. Turbide Vesicle formation during reticulocyte maturation: Association of plasma-membrane activities with released vesicles (exosomes) J. Biol. Chem. 262 1987 9412-9420
27. R.M. Johnstone A. Bianchini and K. Teng Reticulocyte maturation and exosome release: Transferrin receptor containing exosomes shows multiple plasma membrane functions Blood 74 1989 1844-1851
28. P.J. Peters et al. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes Eur. J. Immunol. 19 1989 1469-1475
29. G. Raposo et al. B lymphocytes secrete antigen presenting vesicles J. Exp. Med. 183 1996 1161-1172
30. H.F. Heijnen A.E. Schiel R. Fijnheer H.J. Geuze and J.J. Sixma Activated plates release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules Blood 94 1999 3791-3799
31. C. Thery et al. Molecular characterization of dendritic cell derived exosomes: Selective accumulation of the heat shock protein Hsc73 J. Cell Biol. 147 1999 599-610
32. J. Wolfers et al. Tumor derived exosomes are a source of shared tumor rejection antigens for CTL crosspriming Nat. Med. 7 2001 297-303
33. G. van Niel M. Heyman The epithelial cell cytoskeleton and intracellular trafficking. II. Intestinal epithelial cell exosomes: Perspectives on their structure and function Am. J. Physiol. Gastrointest. Liver Physiol. 283 2002 G251-G255
34. J.M. Escola M.J. Kleijmeer W. Stoorvogel J.M. Griffith O. Yoshie and H.J. Geuze Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes J. Biol. Chem. 273 1998 20121-20127
35. C. Thery et al. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles J. Immunol. 166 2001 7309-7318
36. L. Zitvogel et al. Eradication of established murine tumors using a novel cell free vaccine: Dendritic cell derived exosomes Nat. Med. 4 1998 594-600
37. F. Andre et al. Exosomes in cancer immunotherapy: Preclinical data Adv. Exp. Med. Biol. 495 2001 349-354
38. M.A. Morse et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer J. Transl. Med. 3 2005 9-16
39. M. Karlsson S. Lundin U. Dahlgren H. Kahu I. Pettersson and E. Telemo Tolerosomes are produced by intestinal epithelial cells Eur. J. Immunol. 31 2001 2892-2900
40. G. Andreola et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles J. Exp. Med. 195 2002 1303-1316
41. M.J. Martinez-Lorenzo et al., Activated human T cells release bioactive Fas ligand and APO2 ligand microvesicle J. Immunol. 163 1999 1274-1281
42. S.-H. Kim et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis J. Immunol. 174 2005 6440-6448
43. W. Ptak W.R. Herzog and P.W. Askenase Delayed-type hypersensitivity initiation by early-acting cells that are antigen mismatched or MHC incompatible with late-acting, delayed-type hypersensitivity effector T cells J. Immunol. 146 1991 469-475
44. A.E. Morelli et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells Blood 104 2004 3257-3266